A laser treatment for each glaucoma stage

As a world leader in lasers in Ophthalmology,
Lumibird Medical offer a comprehensive approach to Glaucoma LASER Therapy with treatment options at every stage of the disease paradigm.

Today, ophthalmologists can offer advanced glaucoma laser treatment options to patients, with greater safety and efficacy than ever before.

As a world leader in lasers in Ophthalmology,
Lumibird Medical offer a comprehensive approach to Glaucoma LASER Therapy with treatment options at every stage of the disease paradigm.

Today, ophthalmologists can offer advanced glaucoma laser treatment options to patients, with greater safety and efficacy than ever before.

Selective Laser Trabeculoplasty (SLT)

First Line Treatment

A first-line treatment for primary open angle glaucoma, POAG, and ocular hypertension, supporting a change in clinical practice. Improves porosity of the Trabecular Meshwork for optimal aqueous outflow, while preserving the underlying Trabecular structures.

SubCyclo

Second Line Treatment

A modern laser therapy, preserving ciliary epithelium while reducing aqueous production and improving uveoscleral outflow, substantially reducing IOP at any stage of the Glaucoma condition.

Thermocyclo

Last resort treatment

The traditional laser approach toward end-stage, refractory Glaucoma. Turning off the aqueous inlet tap through tightly controlled thermal destruction of the ciliary process.

Easily access to our clinical database

LATEST CLINICAL DATA

Access a range of clinical educational content, to all the clinical content available about for both macula and peripheral treatments, including: clinical articles, clinical videos, treatment guidelines…

From first-line to refractory: Integrating SLT and SubCyclo

22/01/2026

The “drops first, everything else later” era is coming to an end. Dr Mark Chiang (Australia) shares his laser-first approach to glaucoma management: SLT to match first-line drop efficacy without the burden of daily medication, SubCyclo for patients who fail or cannot tolerate earlier treatments, and stents for the right surgical candidates.

Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial 3- and 6-year study results summary

14/05/2025

Summary of the 3- and 6-year study results of the LiGHT study.

Selective Laser Trabeculoplasty as a First-line Treatment

17/05/2023

The glaucoma surgical landscape is evolving and changing dramatically as we move forward in the era of interventional glaucoma. The interventional glaucoma mindset represents a significant paradigm shift in patient care, taking the treatment burden out of the patient’s hands and placing more emphasis on earlier laser intervention.

SLT: Positive implications from the LiGHT study

07/03/2023

Glaucoma is a lifelong disease that requires continual monitoring and management. For many patients, glaucoma can be controlled medically—at least for a time—but the treatment is far from perfect. Complications, side effects, and compliance are common issues for those who rely on eye drops to control IOP. Other barriers to medical treatment include nonresponse to a medication, tachyphylaxis, and financial burden.

SLT as Frontline Therapy

19/12/2022

Selective laser trabeculoplasty (SLT) has come a long way in the last few years. The practice is gaining adherents as a first-line treatment for open-angle glaucoma for multiple reasons. And to give SLT a boost and provide an uber-coherent overview of the reasons in favor of SLT, Dr. Paul Singh spoke on its behalf at ESCRS 2022 in Milan.

Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial 3- and 6-year study results summary

14/05/2025

Summary of the 3- and 6-year study results of the LiGHT study.

Selective Laser Trabeculoplasty as a First-line Treatment

17/05/2023

A laser treatment for each glaucoma stage

Easily access to our clinical database

LATEST CLINICAL DATA

From first-line to refractory: Integrating SLT and SubCyclo

Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial 3- and 6-year study results summary

Selective Laser Trabeculoplasty as a First-line Treatment

SLT: Positive implications from the LiGHT study

SLT as Frontline Therapy

Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial 3- and 6-year study results summary

Selective Laser Trabeculoplasty as a First-line Treatment

More info

Newsletter